Search

Your search keyword '"Kagawa, Naoki"' showing total 7 results
Start Over Author "Kagawa, Naoki" Publisher biomed central
7 results on '"Kagawa, Naoki"'

1. Correction: Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort

Author

Hayashi, Nobuhide, Fukai, Junya, Nakatogawa, Hirokazu, Kawaji, Hiroshi, Yoshioka, Ema, Kodama, Yoshinori, Nakajo, Kosuke, Uda, Takehiro, Naito, Kentaro, Kijima, Noriyuki, Okita, Yoshiko, Kagawa, Naoki, Takahashi, Yoshinobu, Hashimoto, Naoya, Arita, Hideyuki, Takano, Koji, Sakamoto, Daisuke, Iida, Tomoko, Arakawa, Yoshiki, Kawauchi, Takeshi, Sonoda, Yukihiko, Mitobe, Yuta, Ishibashi, Kenichi, Matsuda, Masahide, Achiha, Takamune, Tomita, Takahiro, Nonaka, Masahiro, Hara, Keijiro, Takebe, Noriyoshi, Tsuzuki, Takashi, Nakajima, Yoshikazu, Ohue, Shiro, Nakajima, Nobuyuki, Watanabe, Akira, Inoue, Akihiro, Umegaki, Masao, Kanematsu, Daisuke, Katsuma, Asako, Sumida, Miho, Shofuda, Tomoko, Mano, Masayuki, Kinoshita, Manabu, Mori, Kanji, Nakao, Naoyuki, and Kanemura, Yonehiro

Published
2024
Full Text
View/download PDF

2. Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort

Author

Hayashi, Nobuhide, Fukai, Junya, Nakatogawa, Hirokazu, Kawaji, Hiroshi, Yoshioka, Ema, Kodama, Yoshinori, Nakajo, Kosuke, Uda, Takehiro, Naito, Kentaro, Kijima, Noriyuki, Okita, Yoshiko, Kagawa, Naoki, Takahashi, Yoshinobu, Hashimoto, Naoya, Arita, Hideyuki, Takano, Koji, Sakamoto, Daisuke, Iida, Tomoko, Arakawa, Yoshiki, Kawauchi, Takeshi, Sonoda, Yukihiko, Mitobe, Yuta, Ishibashi, Kenichi, Matsuda, Masahide, Achiha, Takamune, Tomita, Takahiro, Nonaka, Masahiro, Hara, Keijiro, Takebe, Noriyoshi, Tsuzuki, Takashi, Nakajima, Yoshikazu, Ohue, Shiro, Nakajima, Nobuyuki, Watanabe, Akira, Inoue, Akihiro, Umegaki, Masao, Kanematsu, Daisuke, Katsuma, Asako, Sumida, Miho, Shofuda, Tomoko, Mano, Masayuki, Kinoshita, Manabu, Mori, Kanji, Nakao, Naoyuki, and Kanemura, Yonehiro

Published
2024
Full Text
View/download PDF

3. Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

Author

Fukuoka, Kohei, Kurihara, Jun, Shofuda, Tomoko, Kagawa, Naoki, Yamasaki, Kai, Ando, Ryo, Ishida, Joji, Kanamori, Masayuki, Kawamura, Atsufumi, Park, Young-Soo, Kiyotani, Chikako, Akai, Takuya, Keino, Dai, Miyairi, Yosuke, Sasaki, Atsushi, Hirato, Junko, Inoue, Takeshi, Nakazawa, Atsuko, Koh, Katsuyoshi, Nishikawa, Ryo, Date, Isao, Nagane, Motoo, Ichimura, Koichi, and Kanemura, Yonehiro

Published
2023
Full Text
View/download PDF

5. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors

Author

Fukuoka, Kohei, Kanemura, Yonehiro, Shofuda, Tomoko, Fukushima, Shintaro, Yamashita, Satoshi, Narushima, Daichi, Kato, Mamoru, Honda-Kitahara, Mai, Ichikawa, Hitoshi, Kohno, Takashi, Sasaki, Atsushi, Hirato, Junko, Hirose, Takanori, Komori, Takashi, Satomi, Kaishi, Yoshida, Akihiko, Yamasaki, Kai, Nakano, Yoshiko, Takada, Ai, Nakamura, Taishi, Takami, Hirokazu, Matsushita, Yuko, Suzuki, Tomonari, Nakamura, Hideo, Makino, Keishi, Sonoda, Yukihiko, Saito, Ryuta, Tominaga, Teiji, Matsusaka, Yasuhiro, Kobayashi, Keiichi, Nagane, Motoo, Furuta, Takuya, Nakada, Mitsutoshi, Narita, Yoshitaka, Hirose, Yuichi, Ohba, Shigeo, Wada, Akira, Shimizu, Katsuyoshi, Kurozumi, Kazuhiko, Date, Isao, Fukai, Junya, Miyairi, Yousuke, Kagawa, Naoki, Kawamura, Atsufumi, Yoshida, Makiko, Nishida, Namiko, Wataya, Takafumi, Yamaoka, Masayoshi, Tsuyuguchi, Naohiro, Uda, Takehiro, Takahashi, Mayu, Nakano, Yoshiteru, Akai, Takuya, Izumoto, Shuichi, Nonaka, Masahiro, Yoshifuji, Kazuhisa, Kodama, Yoshinori, Mano, Masayuki, Ozawa, Tatsuya, Ramaswamy, Vijay, Taylor, Michael D., Ushijima, Toshikazu, Shibui, Soichiro, Yamasaki, Mami, Arai, Hajime, Sakamoto, Hiroaki, Nishikawa, Ryo, Ichimura, Koichi, and on behalf of the Japan Pediatric Molecular Neuro-Oncology Group (JPMNG)

Published
2018
Full Text
View/download PDF

6. Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts.

Author

Umehara, Toru, Arita, Hideyuki, Yoshioka, Ema, Shofuda, Tomoko, Kanematsu, Daisuke, Kinoshita, Manabu, Kodama, Yoshinori, Mano, Masayuki, Kagawa, Naoki, Fujimoto, Yasunori, Okita, Yoshiko, Nonaka, Masahiro, Nakajo, Kosuke, Uda, Takehiro, Tsuyuguchi, Naohiro, Fukai, Junya, Fujita, Koji, Sakamoto, Daisuke, Mori, Kanji, and Kishima, Haruhiko

Subjects
GLIOBLASTOMA multiforme, MOLECULAR diagnosis, BIOLOGICAL tags, DNA copy number variations
Abstract

The diagnosis and prognostication of glioblastoma (GBM) remain to be solely dependent on histopathological findings and few molecular markers, despite the clinical heterogeneity in this entity. To address this issue, we investigated the prognostic impact of copy number alterations (CNAs) using two population-based IDH-wild-type GBM cohorts: an original Japanese cohort and a dataset from The Cancer Genome Atlas (TCGA). The molecular disproportions between these cohorts were dissected in light of cohort differences in GBM. The Japanese cohort was collected from cases registered in Kansai Molecular Diagnosis Network for CNS tumors (KNBTG). The somatic landscape around CNAs was analyzed for 212 KNBTG cases and 359 TCGA cases. Next, the clinical impacts of CNA profiles were investigated for 140 KNBTG cases and 152 TCGA cases treated by standard adjuvant therapy using temozolomide-based chemoradiation. The comparative profiling indicated unequal distribution of specific CNAs such as EGFR, CDKN2A, and PTEN among the two cohorts. Especially, the triple overlap CNAs in these loci (triple CNA) were much higher in frequency in TCGA (70.5%) than KNBTG (24.3%), and its prognostic impact was independently validated in both cohorts. The KNBTG cohort significantly showed better prognosis than the TCGA cohort (median overall survival 19.3 vs 15.6 months). This survival difference between the two cohorts completely resolved after subclassifying all cases according to the triple CNA status. The prognostic significance of triple CNA was identified in IDH-wild-type GBM. Distribution difference in prognostic CNA profiles potentially could cause survival differences across cohorts in clinical studies. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

7. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.

Author

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, and Ichimura K

Subjects
Adult, Antineoplastic Agents, Alkylating therapeutic use, Biomarkers, Tumor genetics, Brain Neoplasms drug therapy, Brain Neoplasms radiotherapy, Brain Neoplasms surgery, Cohort Studies, Combined Modality Therapy, Dacarbazine analogs & derivatives, Dacarbazine therapeutic use, Female, Glioblastoma drug therapy, Glioblastoma radiotherapy, Glioblastoma surgery, Humans, Isocitrate Dehydrogenase genetics, Japan, Male, Middle Aged, Mutation, Survival Analysis, Temozolomide, Brain Neoplasms genetics, DNA Methylation, DNA Modification Methylases genetics, DNA Repair Enzymes genetics, Glioblastoma genetics, Promoter Regions, Genetic, Telomerase genetics, Tumor Suppressor Proteins genetics
Abstract

The prognostic impact of TERT mutations has been controversial in IDH-wild tumors, particularly in glioblastomas (GBM). The controversy may be attributable to presence of potential confounding factors such as MGMT methylation status or patients' treatment. This study aimed to evaluate the impact of TERT status on patient outcome in association with various factors in a large series of adult diffuse gliomas. We analyzed a total of 951 adult diffuse gliomas from two cohorts (Cohort 1, n = 758; Cohort 2, n = 193) for IDH1/2, 1p/19q, and TERT promoter status. The combined IDH/TERT classification divided Cohort 1 into four molecular groups with distinct outcomes. The overall survival (OS) was the shortest in IDH wild-type/TERT mutated groups, which mostly consisted of GBMs (P < 0.0001). To investigate the association between TERT mutations and MGMT methylation on survival of patients with GBM, samples from a combined cohort of 453 IDH-wild-type GBM cases treated with radiation and temozolomide were analyzed. A multivariate Cox regression model revealed that the interaction between TERT and MGMT was significant for OS (P = 0.0064). Compared with TERT mutant-MGMT unmethylated GBMs, the hazard ratio (HR) for OS incorporating the interaction was the lowest in the TERT mutant-MGMT methylated GBM (HR, 0.266), followed by the TERT wild-type-MGMT methylated (HR, 0.317) and the TERT wild-type-MGMT unmethylated GBMs (HR, 0.542). Thus, patients with TERT mutant-MGMT unmethylated GBM have the poorest prognosis. Our findings suggest that a combination of IDH, TERT, and MGMT refines the classification of grade II-IV diffuse gliomas.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results